Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lilly (NYSE: LLY) has been a major winner from this boom. The drugmaker's Zepbound is one of the best-selling ...